CMG Pharmaceutical, a subsidiary of South Korea's CHA Biotech, said on Monday that it is moving into the pet nutrition supplement market by acquiring ING Medix, a specialist in animal nutrition, and making it a subsidiary.
CMG explained that it expects to create synergies by combining ING Medix's nutritional know-how for companion animals with its own technology and distribution network.
"We will achieve annual sales of 50 billion won ($40 million) in the companion animal market by 2030 through continuous development of new products and partnerships with other companies," said Lee Joo-hyung, CEO of CMG Pharmaceutical.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.